Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial
Authors:
- 28 February 2007
- journal article
- research article
- Published by Springer Nature in Osteoporosis International
- Vol. 18 (8) , 1047-1061
Abstract
Treatment with alendronate (Fosamax®) has been shown to significantly reduce the risk of fragility fractures. Cost-effectiveness of treatment was assessed in nine European countries in a Markov model and was generally found to be cost effective in women with a previous spine fracture.Keywords
This publication has 50 references indexed in Scilit:
- Health care costs of women with symptomatic vertebral fracturesBone, 2004
- Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal WomenNew England Journal of Medicine, 2004
- Pharmacoeconomic Analysis of Bemiparin and Enoxaparin as Prophylaxis for Venous Thromboembolism in Total Knee Replacement SurgeryPharmacoEconomics, 2004
- Cost Effectiveness of Alendronate (Fosamax??) for the Treatment of Osteoporosis and Prevention of FracturesPharmacoEconomics, 2003
- Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical SynthesisJournal of Bone and Mineral Research, 2000
- Methodology. Health-state utilities in a general population in relation to age, gender and socioeconomic factorsEuropean Journal of Public Health, 1999
- Cost Effectiveness of Multi-Therapy Treatment Strategies in the Prevention of Vertebral Fractures in Postmenopausal Women with OsteoporosisPharmacoEconomics, 1998
- The cost of a hip fracture: Estimates for 1,709 patients in SwedenActa Orthopaedica, 1997
- Cost-effectiveness of Fracture Prevention in Established OsteoporosisScandinavian Journal of Rheumatology, 1996
- Hip fractures: A worldwide problem today and tomorrowBone, 1993